Chronic Lymphocytic Leukemia | Clinical

Part 2: Venetoclax and PI3K Inhibition for Relapsed/Refractory CLL

November 22, 2021

During a live virtual event, Danielle Brander, MD, discussed with participating physicians second-line treatment options for patients with chronic lymphocytic leukemia, with questions guided by Targeted Oncology.

Part 1: BTK Inhibitors for CLL in the Second Line

November 18, 2021

During a live virtual event, Danielle Brander, MD, discussed with participating physicians second-line treatment options for patients with chronic lymphocytic leukemia, with questions guided by Targeted Oncology.

Liso-cel With Concurrent Ibrutinib Shows Early Outcomes Improvement in R/R CLL

November 16, 2021

The effects observed with concurrent ibrutinib and lisocabtagene maraleucel in the relapsed or refractory chronic lymphocytic leukeima population included changes in gene signatures related to proliferation, inflammation, and T cell exhaustion.